论文部分内容阅读
目的分析髓系来源的抑制细胞(myeloid-derived suppressor cells,MDSC)在膀胱癌患者外周血中的分布,初步探讨其临床意义。方法采用流式细胞术检测62例膀胱癌患者及20例健康人外周血中MDSC的比例,分析MDSC比例与临床病理特征和CD4+CD25high调节性T细胞(Treg)的关系。结果与正常对照(0.122±0.043)%相比,膀胱癌患者外周血中MDSC比例明显增加(0.679±0.438)%,二者差异有显著性(P<0.01);手术后,患者外周血中MDSC的比例明显下降,与术前比较有统计学意义(P<0.05);MDSC水平与膀胱癌肿瘤分期明显相关,而与肿瘤的分化程度和患者外周血Treg水平无显著相关(P>0.05)。结论膀胱癌患者外周血MDSC细胞水平明显升高,可能与肿瘤免疫功能低下及肿瘤发生发展密切相关。
Objective To analyze the distribution of myeloid-derived suppressor cells (MDSC) in the peripheral blood of patients with bladder cancer and to explore its clinical significance. Methods Flow cytometry was used to detect the percentage of MDSC in peripheral blood of 62 patients with bladder cancer and 20 healthy controls. The relationship between the proportion of MDSC and the clinicopathologic features and CD4 + CD25high regulatory T cells (Tregs) was analyzed. Results Compared with the normal control (0.122 ± 0.043)%, the percentage of MDSC in peripheral blood of patients with bladder cancer increased significantly (0.679 ± 0.438)%, and the difference was significant (P <0.01). After operation, (P <0.05). The level of MDSC was significantly correlated with the stage of tumor in bladder cancer, but not with the degree of tumor differentiation and the level of Treg in peripheral blood (P> 0.05). Conclusion The level of MDSC in peripheral blood of patients with bladder cancer is significantly increased, which may be closely related to the low immune function and tumor development.